111 results on '"Denis, Cécile V."'
Search Results
2. The Role of Platelets and von Willebrand Factor in the Procoagulant Phenotype of Inflammatory Bowel Disease.
- Author
-
Schellenberg, Célia, Lagrange, Jérémy, Ahmed, Muhammad Usman, Arnone, Djésia, Campoli, Philippe, Louis, Huguette, Touly, Nina, Caron, Bénédicte, Plénat, François, Perrin, Julien, Lenting, Peter J, Regnault, Véronique, Lacolley, Patrick, Denis, Cécile V, and Peyrin-Biroulet, Laurent
- Abstract
Aims Although the risk of thrombosis is well documented for inflammatory bowel disease [IBD] patients, the underlying pathological mechanism seems to be different from other thrombotic conditions. Determining the factors responsible for the increased risk of thrombosis in IBD would help to improve the management of this frequent complication. Methods We studied the interplay between platelets, coagulation, and von Willebrand factor [VWF] in 193 IBD patients and in experimental models [acute and chronic] of colitis in wild-type and VWF-deficient mice. Results We found a platelet-dependent increase in thrombin generation in IBD patients and in our mouse model of colitis. Agglutinated platelets were present in the blood of patients and mice. Interestingly, we observed not only a significant increase in total VWF antigen, but we were also able to detect the presence of active VWF [VWF in its platelet-binding conformation; 3.2 ± 2.7 μg/mL] in the plasma of 30% of all IBD patients. In healthy controls, active VWF levels were <0.3 μg/mL. This led us to further explore experimental colitis in VWF-deficient mice and we observed that these mice were protected against the procoagulant state triggered by the colitis. Unexpectedly, these mice also showed a significant worsening of colitis severity in both acute and chronic models. Conclusion Platelets and VWF [including its active form] appear to be central players in the procoagulant phenotype in IBD. We observed that the role of VWF in haemostasis differs from its role in colonic tissue healing, potentially opening new therapeutic avenues for a life-threatening complication in IBD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Fitusiran reduces bleeding in factor X–deficient mice
- Author
-
Verhenne, Sebastien, McCluskey, Geneviève, Maynadié, Hortense, Adam, Frédéric, Casari, Caterina, Panicot-Dubois, Laurence, Crescence, Lydie, Dubois, Christophe, Denis, Cécile V., Lenting, Peter J., and Christophe, Olivier D.
- Abstract
•Fitusiran is an investigational siRNA reducing antithrombin expression that is under clinical evaluation for the treatment of hemophilia.•Using inducible FX–deficient mice, we demonstrate that fitusiran has the potential to improve hemostasis in FX deficiency.
- Published
- 2024
- Full Text
- View/download PDF
4. Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy
- Author
-
Mimoun, Angelina, Bou-Jaoudeh, Melissa, Delignat, Sandrine, Daventure, Victoria, Reyes Ruiz, Alejandra, Lecerf, Maxime, Azam, Aurélien, Noe, Remi, Peyron, Ivan, Christophe, Olivier D., Lenting, Peter J., Proulle, Valérie, McIntosh, Jenny, Nathwani, Amit C., Dimitrov, Jordan D., Denis, Cécile V., and Lacroix-Desmazes, Sébastien
- Abstract
Transplacental delivery of maternal immunoglobulin G (IgG) provides humoral protection during the first months of life until the newborn’s immune system reaches maturity. The maternofetal interface has been exploited therapeutically to replace missing enzymes in the fetus, as shown in experimental mucopolysaccharidoses, or to shape adaptive immune repertoires during fetal development and induce tolerance to self-antigens or immunogenic therapeutic molecules.
- Published
- 2023
- Full Text
- View/download PDF
5. Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models
- Author
-
Roullet, Stéphanie, Luc, Norman, Rayes, Julie, Solarz, Jean, Disharoon, Dante, Ditto, Andrew, Gahagan, Emily, Pawlowski, Christa, Sefiane, Thibaud, Adam, Frédéric, Casari, Caterina, Christophe, Olivier D., Bruckman, Michael, Lenting, Peter J., Sen Gupta, Anirban, and Denis, Cécile V.
- Abstract
•SP nanoparticles improve thrombus formation on collagen using blood from VWD murine models.•Treatment with SP nanoparticles reduces blood loss in murine models of VWD.
- Published
- 2023
- Full Text
- View/download PDF
6. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor
- Author
-
Barbon, Elena, Kawecki, Charlotte, Marmier, Solenne, Sakkal, Aboud, Collaud, Fanny, Charles, Severine, Ronzitti, Giuseppe, Casari, Caterina, Christophe, Olivier D., Denis, Cécile V., Lenting, Peter J., and Mingozzi, Federico
- Abstract
Von Willebrand disease (VWD), the most common inherited bleeding disorder in humans, is caused by quantitative or qualitative defects in von Willebrand factor (VWF). VWD represents a potential target for gene therapy applications, as a single treatment could potentially result in a long-term correction of the disease. In recent years, several liver-directed gene therapy approaches have been exploited for VWD, but their efficacy was generally limited by the large size of the VWF transgene and the reduced hemostatic activity of the protein produced from hepatocytes. In this context, we aimed at developing a gene therapy strategy for gene delivery into endothelial cells, the natural site of biosynthesis of VWF. We optimized an endothelial-specific dual hybrid AAV vector, in which the large VWF cDNA was put under the control of an endothelial promoter and correctly reconstituted upon cell transduction by a combination of trans-splicing and homologous recombination mechanisms. In addition, we modified the AAV vector capsid by introducing an endothelial-targeting peptide to improve the efficiency for endothelial-directed gene transfer. This vector platform allowed the reconstitution of full-length VWF transgene both in vitro in human umbilical vein endothelial cells and in vivo in VWD mice, resulting in long-term expression of VWF.
- Published
- 2023
- Full Text
- View/download PDF
7. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD
- Author
-
Kizlik-Masson, Claire, Peyron, Ivan, Gangnard, Stéphane, Le Goff, Gaelle, Lenoir, Solen M, Damodaran, Sandra, Clavel, Marie, Roullet, Stéphanie, Regnault, Véronique, Rauch, Antoine, Vincent, Flavien, Jeanpierre, Emmanuelle, Dupont, Annabelle, Ternisien, Catherine, Donnet, Thibault, Christophe, Olivier D., van Belle, Eric, Denis, Cécile V., Casari, Caterina, Susen, Sophie, and Lenting, Peter J.
- Abstract
von Willebrand factor (VWF) is a multimeric protein, the size of which is regulated via ADAMTS13-mediated proteolysis within the A2 domain. We aimed to isolate nanobodies distinguishing between proteolyzed and non-proteolyzed VWF, leading to the identification of a nanobody (designated KB-VWF-D3.1) targeting the A3 domain, the epitope of which overlaps the collagen-binding site. Although KB-VWF-D3.1 binds with similar efficiency to dimeric and multimeric derivatives of VWF, binding to VWF was lost upon proteolysis by ADAMTS13, suggesting that proteolysis in the A2 domain modulates exposure of its epitope in the A3 domain. We therefore used KB-VWF-D3.1 to monitor VWF degradation in plasma samples. Spiking experiments showed that a loss of 10% intact VWF could be detected using this nanobody. By comparing plasma from volunteers to that from congenital von Willebrand disease (VWD) patients, intact-VWF levels were significantly reduced for all VWD types, and most severely in VWD type 2A–group 2, in which mutations promote ADAMTS13-mediated proteolysis. Unexpectedly, we also observed increased proteolysis in some patients with VWD type 1 and VWD type 2M. A significant correlation (r = 0.51, P < .0001) between the relative amount of high–molecular weight multimers and levels of intact VWF was observed. Reduced levels of intact VWF were further found in plasmas from patients with severe aortic stenosis and patients receiving mechanical circulatory support. KB-VWF-D3.1 is thus a nanobody that detects changes in the exposure of its epitope within the collagen-binding site of the A3 domain. In view of its unique characteristics, it has the potential to be used as a diagnostic tool to investigate whether a loss of larger multimers is due to ADAMTS13-mediated proteolysis.
- Published
- 2023
- Full Text
- View/download PDF
8. A gain‐of‐function filamin A mutation in mouse platelets induces thrombus instability
- Author
-
Adam, Frédéric, Kauskot, Alexandre, Lamrani, Lamia, Solarz, Jean, Soukaseum, Christelle, Repérant, Christelle, Denis, Cécile V., Raslova, Hana, Rosa, Jean‐Philippe, and Bryckaert, Marijke
- Abstract
Filaminopathies A are rare disorders affecting the brain, intestine, or skeleton, characterized by dominant X‐linked filamin A (FLNA) gene mutations. Macrothrombocytopenia with functionally defective platelets is frequent. We have described a filaminopathy A male patient, exhibiting a C‐terminal frame‐shift FLNa mutation (Berrou et al., Arterioscler Thromb Vasc Biol. 2017;37:1087–1097). Contrasting with female patients, this male patient exhibited gain of platelet functions, including increased platelet aggregation, integrin αIIbβ3 activation, and secretion at low agonist concentration, raising the issue of thrombosis risk. Our goal is to assess the thrombotic potential of the patient FLNa mutation in an in vivomodel. We have established a mutant FlnA knock‐in mouse model. The mutant FlnA mouse platelets phenocopied patient platelets, showing normal platelet count, lower expression level of mutant FlnA, and gain of platelet functions: increased platelet aggregation, secretion, and αIIbβ3 activation, as well as increased spreading and clot retraction. Surprisingly, mutant FlnA mice exhibited a normal bleeding time, but with increased re‐bleeding (77%) compared to wild type (WT) FlnA mice (27%), reflecting hemostatic plug instability. Again, in an in vivothrombosis model, the occlusion time was not altered by the FlnA mutation, but arteriolar embolies were increased (7‐fold more frequent in mutant FlnA mice versus WT mice), confirming thrombus instability. This study shows that the FlnA mutation found in the male patient induced gain of platelet functions in vitro, but thrombus instability in vivo. Implications for the role of FLNa in physiology of thrombus formation are discussed.
- Published
- 2022
- Full Text
- View/download PDF
9. A gain‐of‐function filamin A mutation in mouse platelets induces thrombus instability
- Author
-
Adam, Frédéric, Kauskot, Alexandre, Lamrani, Lamia, Solarz, Jean, Soukaseum, Christelle, Repérant, Christelle, Denis, Cécile V., Raslova, Hana, Rosa, Jean‐Philippe, and Bryckaert, Marijke
- Abstract
Filaminopathies A are rare disorders affecting the brain, intestine, or skeleton, characterized by dominant X‐linked filamin A (FLNA) gene mutations. Macrothrombocytopenia with functionally defective platelets is frequent. We have described a filaminopathy A male patient, exhibiting a C‐terminal frame‐shift FLNa mutation (Berrou et al., Arterioscler Thromb Vasc Biol. 2017;37:1087–1097). Contrasting with female patients, this male patient exhibited gain of platelet functions, including increased platelet aggregation, integrin αIIbβ3 activation, and secretion at low agonist concentration, raising the issue of thrombosis risk.
- Published
- 2022
- Full Text
- View/download PDF
10. Von Willebrand factor and cancer: Another piece of the puzzle
- Author
-
Denis, Cécile V., Roullet, Stéphanie, and Perrin, Julien
- Published
- 2022
- Full Text
- View/download PDF
11. Von Willebrand factor and cancer: Another piece of the puzzle
- Author
-
Denis, Cécile V., Roullet, Stéphanie, and Perrin, Julien
- Published
- 2022
- Full Text
- View/download PDF
12. N-Glycosylation Deficiency Reduces the Activation of Protein C and Disrupts Endothelial Barrier Integrity
- Author
-
Pascreau, Tiffany, Saller, François, Bianchini, Elsa P., Lasne, Dominique, Bruneel, Arnaud, Reperant, Christelle, Foulquier, François, Denis, Cécile V., De Lonlay, Pascale, and Borgel, Delphine
- Published
- 2022
- Full Text
- View/download PDF
13. Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S
- Author
-
Sedzro, Josepha C., Adam, Frédéric, Auditeau, Claire, Bianchini, Elsa, De Carvalho, Allan, Peyron, Ivan, Daramé, Sadyo, Gandrille, Sophie, Thomassen, Stella, Hackeng, Tilman M., Christophe, Olivier D., Lenting, Peter J., Denis, Cécile V., Borgel, Delphine, and Saller, François
- Abstract
Protein S (PS) is a natural anticoagulant acting as a cofactor for activated protein C (APC) in the proteolytic inactivation of activated factors V (FVa) and VIII (FVIIIa), but also for tissue factor pathway inhibitor α (TFPIα) in the inhibition of activated factor X (FXa).
- Published
- 2022
- Full Text
- View/download PDF
14. Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S
- Author
-
Sedzro, Josepha C., Adam, Frédéric, Auditeau, Claire, Bianchini, Elsa, De Carvalho, Allan, Peyron, Ivan, Daramé, Sadyo, Gandrille, Sophie, Thomassen, Stella, Hackeng, Tilman M., Christophe, Olivier D., Lenting, Peter J., Denis, Cécile V., Borgel, Delphine, and Saller, François
- Abstract
Protein S (PS) is a natural anticoagulant acting as a cofactor for activated protein C (APC) in the proteolytic inactivation of activated factors V (FVa) and VIII (FVIIIa), but also for tissue factor pathway inhibitor α (TFPIα) in the inhibition of activated factor X (FXa). For therapeutic purposes, we aimed at generating single‐domain antibodies (sdAbs) that could specifically modulate the APC‐cofactor activity of PS in vivo. A llama‐derived immune library of sdAbs was generated and screened on recombinant human PS by phage display. PS binders were tested in a global activated partial thromboplastin time (APTT)‐based APC‐cofactor activity assay. A PS‐specific sdAb (PS003) was found to enhance the APC‐cofactor activity of PS in our APTT‐based assay, and this enhancing effect was greater for a bivalent form of PS003 (PS003biv). Further characterization of PS003biv demonstrated that PS003biv also enhanced the APC‐cofactor activity of PS in a tissue factor (TF)‐induced thrombin generation assay and stimulated APC in the inactivation of FVa, but not FVIIIa, in plasma‐based assays. Furthermore, PS003biv was directed against the sex hormone‐binding globulin (SHBG)‐like domain but did not inhibit the binding of PS to C4b‐binding protein (C4BP) and did not interfere with the TFPIα‐cofactor activity of PS. In mice, PS003biv exerted an antithrombotic effect in a FeCl3‐induced thrombosis model, while not affecting physiological hemostasis in a tail‐clip bleeding model. Altogether, these results showed that pharmacological enhancement of the APC‐cofactor activity of PS through an original anti‐PS sdAb might constitute a promising and safe antithrombotic strategy.
- Published
- 2022
- Full Text
- View/download PDF
15. von Willebrand disease: what does the future hold?
- Author
-
Denis, Cécile V., Susen, Sophie, and Lenting, Peter J.
- Abstract
von Willebrand disease (VWD) is characterized by its heterogeneous clinical manifestation, which complicates its diagnosis and management. The clinical management of VWD has remained essentially unchanged over the last 30 years or so, using von Willebrand factor (VWF) concentrates, desmopressin, and anti–fibrinolytic agents as main tools to control bleeding. This is in contrast to hemophilia A, for which a continuous innovative path has led to novel treatment modalities. Despite current VWD management being considered effective, quality-of-life studies consistently reveal a higher than anticipated burden of VWD on patients, which is particularly true for women. Apparently, despite our perceived notion of current therapeutic efficiency, there is space for innovation with the goal of reaching superior efficacy. Developing innovative treatments for VWD is complex, especially given the heterogeneity of the disease and the multifunctional nature of VWF. In this perspective article, we describe several potential strategies that could provide the basis for future VWD treatments. These include genetic approaches, such as gene therapy using dual-vector adenoassociated virus and transcriptional silencing of mutant alleles. Furthermore, protein-based approaches to increase factor FVIII levels in VWD-type 3 or 2N patients are discussed. Finally, antibody-based options to interfere with VWF degradation (for congenital VWD-type 2A or acquired von Willebrand syndrome-type 2A) or increase endogenous VWF levels (for VWD-type 1) are presented. By highlighting these potential strategies, we hope to initiate an innovative path, which ultimately would allow us to better serve VWD patients and their specific needs.
- Published
- 2021
- Full Text
- View/download PDF
16. von Willebrand disease: what does the future hold?
- Author
-
Denis, Cécile V., Susen, Sophie, and Lenting, Peter J.
- Abstract
von Willebrand disease (VWD) is characterized by its heterogeneous clinical manifestation, which complicates its diagnosis and management. The clinical management of VWD has remained essentially unchanged over the last 30 years or so, using von Willebrand factor (VWF) concentrates, desmopressin, and anti–fibrinolytic agents as main tools to control bleeding. This is in contrast to hemophilia A, for which a continuous innovative path has led to novel treatment modalities. Despite current VWD management being considered effective, quality-of-life studies consistently reveal a higher than anticipated burden of VWD on patients, which is particularly true for women. Apparently, despite our perceived notion of current therapeutic efficiency, there is space for innovation with the goal of reaching superior efficacy. Developing innovative treatments for VWD is complex, especially given the heterogeneity of the disease and the multifunctional nature of VWF. In this perspective article, we describe several potential strategies that could provide the basis for future VWD treatments. These include genetic approaches, such as gene therapy using dual-vector adenoassociated virus and transcriptional silencing of mutant alleles. Furthermore, protein-based approaches to increase factor FVIII levels in VWD-type 3 or 2N patients are discussed. Finally, antibody-based options to interfere with VWF degradation (for congenital VWD-type 2A or acquired von Willebrand syndrome-type 2A) or increase endogenous VWF levels (for VWD-type 1) are presented. By highlighting these potential strategies, we hope to initiate an innovative path, which ultimately would allow us to better serve VWD patients and their specific needs.
- Published
- 2021
- Full Text
- View/download PDF
17. Anti-inflammatory Activity of the Protein Z-Dependent Protease Inhibitor
- Author
-
Razanakolona, Mahita, Adam, Frédéric, Bianchini, Elsa, Saller, François, Carvalho, Allan de, Diehl, Jean-Luc, Denis, Cécile V., Meziani, Ferhat, Borgel, Delphine, Helms, Julie, and Vasse, Marc
- Published
- 2021
- Full Text
- View/download PDF
18. TaSER: Combining forces to stop the clot
- Author
-
Denis, Cécile V., Lenting, Peter J., and Wahl, Denis
- Published
- 2022
- Full Text
- View/download PDF
19. TaSER: Combining forces to stop the clot
- Author
-
Denis, Cécile V., Lenting, Peter J., and Wahl, Denis
- Published
- 2022
- Full Text
- View/download PDF
20. In vivo modulation of a dominant‐negative variant in mouse models of von Willebrand disease type 2A
- Author
-
Campioni, Matteo, Legendre, Paulette, Loubiere, Cécile, Lunghi, Barbara, Pinotti, Mirko, Christophe, Olivier D., Lenting, Peter J., Denis, Cécile V., Bernardi, Francesco, and Casari, Caterina
- Abstract
Unlabelled Boxce:textbox-body/
- Published
- 2021
- Full Text
- View/download PDF
21. In vivo modulation of a dominant‐negative variant in mouse models of von Willebrand disease type 2A
- Author
-
Campioni, Matteo, Legendre, Paulette, Loubiere, Cécile, Lunghi, Barbara, Pinotti, Mirko, Christophe, Olivier D., Lenting, Peter J., Denis, Cécile V., Bernardi, Francesco, and Casari, Caterina
- Abstract
EssentialsTreatment options for von Willebrand disease (VWD) patients are limited.The p.P1127_C1948delinsR deletion/variant is a useful model to study VWD in vitro and in vivo.Counteracting dominant‐negative effects restores von Willebrand factor multimerization in mice.This is the first siRNA‐based treatment applied to a mouse model of VWD‐type 2A. Treatment options for von Willebrand disease (VWD) patients are limited.The p.P1127_C1948delinsR deletion/variant is a useful model to study VWD in vitro and in vivo.Counteracting dominant‐negative effects restores von Willebrand factor multimerization in mice.This is the first siRNA‐based treatment applied to a mouse model of VWD‐type 2A. Treatment options for patients suffering from von Willebrand disease (VWD) are limited. Von Willebrand factor (VWF) is a polymeric protein that undergoes regulated dimerization and subsequent multimerization during its biosynthesis. Numerous heterozygous variants within the VWFgene display a dominant‐negative effect and result in severe VWD. Previous studies have suggested that preventing the assembly of wild‐type and mutant heteropolymers using siRNAs may have beneficial effects on VWF phenotypes in vitro. To study heterozygous dominant‐negative variants in vivo, we developed a mouse model of VWD‐type 2A and tested two independent strategies to modulate its detrimental effect. The p.P1127_C1948delinsR deletion/variant, causing defective VWF multimerization, was expressed in mice as a model of VWD‐type 2A variant. Two corrective strategies were applied. For the first time in a mouse model of VWD, we applied siRNAs selectively inhibiting translation of the mutant transcripts and we combined the VWD‐type 2A deletion with the Cys to Arg substitution at position 2773, which is known to prevent dimerization. The RNA silencing approach induced a modest but consistent improvement of the VWF multimer profile. However, due to incomplete efficiency, the dominant‐negative effect of the original variant could not be completely prevented. In contrast, the DNA approach resulted in increased antigen levels and restoration of a normal multimer profile. Our data showed that preventing the detrimental impact of dominant‐negative VWF variants by independent molecular mechanisms has beneficial consequences in vivo, in mouse models of dominant VWD.
- Published
- 2021
- Full Text
- View/download PDF
22. Unique humanized mouse models of von Willebrand disease type 2A.
- Author
-
Heestermans, Marco, Mc Cluskey, Geneviève, Peyron, Ivan, Reperant, Christelle, Christophe, Olivier D., Denis, Cécile V., Lenting, Peter J., and Casari, Caterina
- Subjects
BLOOD-vessel abnormalities ,VASCULAR diseases - Abstract
Background: Angiodysplasia is a vascular malformation associated with gastrointestinal bleeding, generally observed in the elderly. This condition is unexpectedly more frequent in patients with von Willebrand disease (VWD)-type 2A having low levels of VWF high-molecular-weight-multimers (HMWMs) and increased VWF-degradation fragments (1). Aim: To develop an innovative murine model of VWD-type 2A and study the role of degraded-VWF in vascular processes. Methods: Mice expressing human (h) VWF, carrying the type 2A (p.R1597W) variant or wild-type (as control) and human GPIba, have been generated (hVWF(p.R1597W) + / +/hGP1BA + / + and hVWF + / +/hGP1BA + / +). Haemoglobin (Hb), VWF:Ag, propeptide, multimer pattern and factor VIII activity were analyzed. Tail-clip and tail-vein-transection (TVT) bleeding assays were assessed. Results: Control hVWF + / +/hGP1BA + / + -mice expressed 15 ± 4% VWF:Ag, 44 ± 8% FVIII activity and normal VWF multimers. hVWF(p. R1597W) + / +/hGP1BA + / + -mice are viable and do not display spontaneous bleeding manifestations. These mice expressed 3 ± 1% VWF:Ag and 7 ± 1% FVIII activity combined with an abnormal multimer pattern, with only low multimers and few degradation bands visible. Despite the relatively low VWF:Ag levels, hVWF + / +/hGP1BA + / + -mice displayed normal haemostatic responses in both the severe- (tail-clip) and milder- (TVT) bleeding assays. In contrast, hVWF(p.R1597W) + / + / hGP1BA + / + -mice had a severe bleeding phenotype. Interestingly, in the TVT model, although the amount of blood shed was consistent with severe bleeding, 57% of type 2A mice were capable of forming an occlusive, although unstable clot within 15 min of the injury, differing from the bleeding profile of VWF-deficient mice. Conclusion: We developed a unique humanized mouse models for VWD-type 2A. Experiments are ongoing to study the vasculature of these mice. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. A Combination of Two Variants p. (Val510 =) and p. (Pro2145Thrfs * 5), Responsible for von Willebrand Disease Type 3 in a Caribbean Patient
- Author
-
Dubois, Marie Daniela, Pierre-Louis, Serge, Rabout, Johalène, Denis, Cécile V., Christophe, Olivier, Susen, Sophie, Goudemand, Jenny, Boisseau, Pierre, Neviere, Rémi, and Pierre-Louis, Olivier
- Published
- 2020
- Full Text
- View/download PDF
24. Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation
- Author
-
Kawecki, Charlotte, Aymonnier, Karen, Ferrière, Stephen, Venisse, Laurence, Arocas, Véronique, Boulaftali, Yacine, Christophe, Olivier D., Lenting, Peter J., Bouton, Marie‐Christine, and Denis, Cécile V.
- Abstract
Protease nexin‐1 (PN‐1) is a member of the serine protease inhibitor (Serpin)‐family, with thrombin as its main target. Current polyclonal and monoclonal antibodies against PN‐1 frequently cross‐react with plasminogen activator inhibitor‐1 (PAI‐1), a structurally and functionally homologous Serpin.
- Published
- 2020
- Full Text
- View/download PDF
25. A hemophilia A mouse model for the in vivo assessment of emicizumab function
- Author
-
Ferrière, Stephen, Peyron, Ivan, Christophe, Olivier D., Kawecki, Charlotte, Casari, Caterina, Muczynski, Vincent, Nathwani, Amit, Kauskot, Alexandre, Lenting, Peter J., and Denis, Cécile V.
- Abstract
The bispecific antibody emicizumab is increasingly used for hemophilia A treatment. However, its specificity for human factors IX and X (FIX and FX) has limited its in vivo functional analysis to primate models of acquired hemophilia. Here, we describe a novel mouse model that allows emicizumab function to be examined. Briefly, FVIII-deficient mice received IV emicizumab 24 hours before tail-clip bleeding was performed. A second infusion with human FIX and FX, administered 5 minutes before bleeding, generated consistent levels of emicizumab (0.7-19 mg/dL for 0.5-10 mg/kg doses) and of both FIX and FX (85 and 101 U/dL, respectively, after dosing at 100 U/kg). Plasma from these mice display FVIII-like activity in assays (diluted activated partial thromboplastin time and thrombin generation), similar to human samples containing emicizumab. Emicizumab doses of 1.5 mg/kg and higher significantly reduced blood loss in a tail-clip–bleeding model using FVIII-deficient mice. However, reduction was incomplete compared with mice treated with human FVIII concentrate, and no difference in efficacy between doses was observed. From this model, we deducted FVIII-like activity from emicizumab that corresponded to a dose of 4.5 U of FVIII per kilogram (ie, 9.0 U/dL). Interestingly, combined with a low FVIII dose (5 U/kg), emicizumab provided enough additive activity to allow complete bleeding arrest. This model could be useful for further in vivo analysis of emicizumab.
- Published
- 2020
- Full Text
- View/download PDF
26. A hemophilia A mouse model for the in vivo assessment of emicizumab function
- Author
-
Ferrière, Stephen, Peyron, Ivan, Christophe, Olivier D., Kawecki, Charlotte, Casari, Caterina, Muczynski, Vincent, Nathwani, Amit, Kauskot, Alexandre, Lenting, Peter J., and Denis, Cécile V.
- Abstract
The bispecific antibody emicizumab is increasingly used for hemophilia A treatment. However, its specificity for human factors IX and X (FIX and FX) has limited its in vivo functional analysis to primate models of acquired hemophilia. Here, we describe a novel mouse model that allows emicizumab function to be examined. Briefly, FVIII-deficient mice received IV emicizumab 24 hours before tail-clip bleeding was performed. A second infusion with human FIX and FX, administered 5 minutes before bleeding, generated consistent levels of emicizumab (0.7-19 mg/dL for 0.5-10 mg/kg doses) and of both FIX and FX (85 and 101 U/dL, respectively, after dosing at 100 U/kg). Plasma from these mice display FVIII-like activity in assays (diluted activated partial thromboplastin time and thrombin generation), similar to human samples containing emicizumab. Emicizumab doses of 1.5 mg/kg and higher significantly reduced blood loss in a tail-clip–bleeding model using FVIII-deficient mice. However, reduction was incomplete compared with mice treated with human FVIII concentrate, and no difference in efficacy between doses was observed. From this model, we deducted FVIII-like activity from emicizumab that corresponded to a dose of 4.5 U of FVIII per kilogram (ie, 9.0 U/dL). Interestingly, combined with a low FVIII dose (5 U/kg), emicizumab provided enough additive activity to allow complete bleeding arrest. This model could be useful for further in vivo analysis of emicizumab.
- Published
- 2020
- Full Text
- View/download PDF
27. A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A
- Author
-
Muczynski, Vincent, Verhenne, Sebastien, Casari, Caterina, Chérel, Ghislaine, Panicot-Dubois, Laurence, Gueguen, Paul, Trossaert, Marc, Dubois, Christophe, Lenting, Peter J., Denis, Cécile V., and Christophe, Olivier D.
- Published
- 2019
- Full Text
- View/download PDF
28. A single‐domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor
- Author
-
Ferrière, Stephen, Kawecki, Charlotte, Ottavi, Jean‐François, Denis, Cécile V., Kauskot, Alexandre, Christophe, Olivier D., and Lenting, Peter J.
- Abstract
Activated factor VII (FVIIa) is pertinent to the initiation of blood coagulation. Proteolytic and amidolytic activity of FVIIa are greatly enhanced by its cofactor, tissue factor (TF).
- Published
- 2019
- Full Text
- View/download PDF
29. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
- Author
-
Aymonnier, Karen, Kawecki, Charlotte, Venisse, Laurence, Boulaftali, Yacine, Christophe, Olivier D., Lenting, Peter J., Arocas, Véronique, de Raucourt, Emmanuelle, Denis, Cécile V., and Bouton, Marie-Christine
- Abstract
Hemophilia A and B, diseases caused by the lack of factor VIII (FVIII) and factor IX (FIX) respectively, lead to insufficient thrombin production, and therefore to bleeding. New therapeutic strategies for hemophilia treatment that do not rely on clotting factor replacement, but imply the neutralization of natural anticoagulant proteins, have recently emerged. We propose an innovative approach consisting of targeting a natural and potent thrombin inhibitor, expressed by platelets, called protease nexin-1 (PN-1). By using the calibrated automated thrombin generation assay, we showed that a PN-1-neutralizing antibody could significantly shorten the thrombin burst in response to tissue factor in platelet-rich plasma (PRP) from patients with mild or moderate hemophilia. In contrast, in PRP from patients with severe hemophilia, PN-1 neutralization did not improve thrombin generation. However, after collagen-induced platelet activation, PN-1 deficiency in F8-/-mice or PN-1 blocking in patients with severe disease led to a significantly improved thrombin production in PRP, underlining the regulatory role of PN-1 released from platelet granules. In various bleeding models, F8-/-/PN-1-/- mice displayed significantly reduced blood loss and bleeding time compared with F8-/-mice. Moreover, platelet recruitment and fibrin(ogen) accumulation were significantly higher in F8-/-/PN-1-/- mice than in F8-/-mice in the ferric chloride-induced mesenteric vessel injury model. Thromboelastometry studies showed enhanced clot stability and lengthened clot lysis time in blood from F8-/-/PN-1-/- and from patients with hemophilia A incubated with a PN-1-neutralizing antibody compared with their respective controls. Our study thus provides proof of concept that PN-1 neutralization can be a novel approach for future clinical care in hemophilia.
- Published
- 2019
- Full Text
- View/download PDF
30. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
- Author
-
Aymonnier, Karen, Kawecki, Charlotte, Venisse, Laurence, Boulaftali, Yacine, Christophe, Olivier D., Lenting, Peter J., Arocas, Véronique, de Raucourt, Emmanuelle, Denis, Cécile V., and Bouton, Marie-Christine
- Abstract
Hemophilia A and B, diseases caused by the lack of factor VIII (FVIII) and factor IX (FIX) respectively, lead to insufficient thrombin production, and therefore to bleeding. New therapeutic strategies for hemophilia treatment that do not rely on clotting factor replacement, but imply the neutralization of natural anticoagulant proteins, have recently emerged. We propose an innovative approach consisting of targeting a natural and potent thrombin inhibitor, expressed by platelets, called protease nexin-1 (PN-1). By using the calibrated automated thrombin generation assay, we showed that a PN-1-neutralizing antibody could significantly shorten the thrombin burst in response to tissue factor in platelet-rich plasma (PRP) from patients with mild or moderate hemophilia. In contrast, in PRP from patients with severe hemophilia, PN-1 neutralization did not improve thrombin generation. However, after collagen-induced platelet activation, PN-1 deficiency in F8−/−mice or PN-1 blocking in patients with severe disease led to a significantly improved thrombin production in PRP, underlining the regulatory role of PN-1 released from platelet granules. In various bleeding models, F8−/−/PN-1−/−mice displayed significantly reduced blood loss and bleeding time compared with F8−/−mice. Moreover, platelet recruitment and fibrin(ogen) accumulation were significantly higher in F8−/−/PN-1−/−mice than in F8−/−mice in the ferric chloride-induced mesenteric vessel injury model. Thromboelastometry studies showed enhanced clot stability and lengthened clot lysis time in blood from F8−/−/PN-1−/−and from patients with hemophilia A incubated with a PN-1-neutralizing antibody compared with their respective controls. Our study thus provides proof of concept that PN-1 neutralization can be a novel approach for future clinical care in hemophilia.
- Published
- 2019
- Full Text
- View/download PDF
31. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab
- Author
-
Atsou, Sénadé, Schellenberg, Célia, Lagrange, Jeremy, Lacolley, Patrick, Lenting, Peter J., Denis, Cécile V., Christophe, Olivier D., and Regnault, Véronique
- Abstract
The effect of factor VIII (FVIII) or emicizumab on thrombin generation is usually assessed in assays using synthetic phospholipids. Here, we assessed thrombin generation at the surface of human arterial cells (aortic endothelial cells [hAECs] and aortic vascular smooth muscle cells [hVSMCs]).
- Published
- 2024
- Full Text
- View/download PDF
32. Von Willebrand factor: how unique structural adaptations support and coordinate its complex function
- Author
-
Lenting, Peter J, Denis, Cécile V, and Christophe, Olivier D
- Abstract
Von Willebrand factor (VWF) is a multimeric protein consisting of covalently linked monomers, which share an identical domain architecture. Although involved in processes like inflammation, angiogenesis and cancer metastasis, VWF is mostly known for its role in hemostasis, by acting as a chaperone-protein for coagulation factor VIII (FVIII) and by contributing to the recruitment of platelets during thrombus formation. To serve its role in hemostasis, VWF needs to bind a variety of ligands, including FVIII, platelet-receptor glycoprotein Ib-alpha, VWF-cleaving protease ADAMTS13, sub-endothelial collagen and integrin alpha-IIb/beta-3. Importantly, interactions are differently regulated for each of these ligands. How are these binding events accomplished and coordinated? The basic structures of the domains that constitute the VWF protein are found in hundreds of other proteins of pro- and eukaryotic organisms. However, the determination of the three-dimensional structures of these domains within the VWF context and especially in complex with its ligands reveals that exclusive, VWF-specific structural adaptations have been incorporated in its domains. They provide an explanation of how VWF binds its ligands in a synchronized and timely fashion. In the current review, we have focused on the domains that interact with the main ligands of VWF and discuss how elucidating the three-dimensional structures of these domains has contributed to our understanding of how VWF function is controlled. We further detail how mutations in these domains that are associated with von Willebrand disease modulate the interaction between VWF and its ligands.
- Published
- 2024
- Full Text
- View/download PDF
33. Platelet Functions are Decreased in Obesity and Restored after Weight Loss: Evidence for a Role of the SERCA3-Dependent ADP Secretion Pathway
- Author
-
Elaïb, Ziane, Lopez, Jose Javier, Coupaye, Muriel, Zuber, Kevin, Becker, Yann, Kondratieff, Aurélie, Repérant, Christelle, Pépin, Marion, Salomon, Laurence, Teillet, France, Msika, Simon, Denis, Cécile V., de Prost, Dominique, Rosa, Jean-Philippe, Bobe, Régis, and Stépanian, Alain
- Published
- 2019
- Full Text
- View/download PDF
34. Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor
- Author
-
Xu, Emma-Ruoqi, von Bülow, Sören, Chen, Po-Chia, Lenting, Peter J., Kolšek, Katra, Aponte-Santamaría, Camilo, Simon, Bernd, Foot, Jaelle, Obser, Tobias, Schneppenheim, Reinhard, Gräter, Frauke, Denis, Cécile V., Wilmanns, Matthias, and Hennig, Janosch
- Abstract
Von Willebrand factor (VWF) is a key player in the regulation of hemostasis by promoting recruitment of platelets to sites of vascular injury. An array of 6 C domains forms the dimeric C-terminal VWF stem. Upon shear force activation, the stem adopts an open conformation allowing the adhesion of VWF to platelets and the vessel wall. To understand the underlying molecular mechanism and associated functional perturbations in disease-related variants, knowledge of high-resolution structures and dynamics of C domains is of paramount interest. Here, we present the solution structure of the VWF C4 domain, which binds to the platelet integrin and is therefore crucial for the VWF function. In the structure, we observed 5 intra- and inter-subdomain disulfide bridges, of which 1 is unique in the C4 domain. The structure further revealed an unusually hinged 2-subdomain arrangement. The hinge is confined to a very short segment around V2547 connecting the 2 subdomains. Together with 2 nearby inter-subdomain disulfide bridges, this hinge induces slow conformational changes and positional alternations of both subdomains with respect to each other. Furthermore, the structure demonstrates that a clinical gain-of-function VWF variant (Y2561) is more likely to have an effect on the arrangement of the C4 domain with neighboring domains rather than impairing platelet integrin binding.
- Published
- 2019
- Full Text
- View/download PDF
35. The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction
- Author
-
Schneppenheim, Reinhard, Hellermann, Natalie, Brehm, Maria A., Klemm, Ulrike, Obser, Tobias, Huck, Volker, Schneider, Stefan W., Denis, Cécile V., Tischer, Alexander, Auton, Matthew, März, Winfried, Xu, Emma-Ruoqi, Wilmanns, Matthias, and Zotz, Rainer B.
- Abstract
The frequent von Willebrand factor (VWF) variant p.Phe2561Tyr is located within the C4 domain, which also harbors the platelet GPIIb/IIIa-binding RGD sequence. To investigate its potential effect on hemostasis, we genotyped 865 patients with coronary artery disease (CAD), 915 with myocardial infarction (MI), and 417 control patients (Ludwigshafen Risk and Cardiovascular Health Study) and performed functional studies of this variant. A univariate analysis of male and female carriers of the Tyr2561 allele aged 55 years or younger revealed an elevated risk for repeated MI (odds ratio, 2.53; 95% confidence interval [CI], 1.07-5.98). The odds ratio was even higher in females aged 55 years or younger, at a value of 5.93 (95% CI, 1.12-31.24). Cone and plate aggregometry showed that compared with Phe2561, Tyr2561 was associated with increased platelet aggregate size both in probands’ blood and with the recombinant variants. Microfluidic assays revealed that the critical shear rate for inducing aggregate formation was decreased to 50% by Tyr2561 compared with Phe2561. Differences in C-domain circular dichroism spectra resulting from Tyr2561 suggest an increased shear sensitivity of VWF as a result of altered association of the C domains that disrupts the normal dimer interface. In summary, our data emphasize the functional effect of the VWF C4 domain for VWF-mediated platelet aggregation in a shear-dependent manner and provide the first evidence that a functional variant of VWF plays a role in arterial thromboembolism.
- Published
- 2019
- Full Text
- View/download PDF
36. The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction
- Author
-
Schneppenheim, Reinhard, Hellermann, Natalie, Brehm, Maria A., Klemm, Ulrike, Obser, Tobias, Huck, Volker, Schneider, Stefan W., Denis, Cécile V., Tischer, Alexander, Auton, Matthew, März, Winfried, Xu, Emma-Ruoqi, Wilmanns, Matthias, and Zotz, Rainer B.
- Abstract
The frequent von Willebrand factor (VWF) variant p.Phe2561Tyr is located within the C4 domain, which also harbors the platelet GPIIb/IIIa-binding RGD sequence. To investigate its potential effect on hemostasis, we genotyped 865 patients with coronary artery disease (CAD), 915 with myocardial infarction (MI), and 417 control patients (Ludwigshafen Risk and Cardiovascular Health Study) and performed functional studies of this variant. A univariate analysis of male and female carriers of the Tyr2561 allele aged 55 years or younger revealed an elevated risk for repeated MI (odds ratio, 2.53; 95% confidence interval [CI], 1.07-5.98). The odds ratio was even higher in females aged 55 years or younger, at a value of 5.93 (95% CI, 1.12-31.24). Cone and plate aggregometry showed that compared with Phe2561, Tyr2561 was associated with increased platelet aggregate size both in probands' blood and with the recombinant variants. Microfluidic assays revealed that the critical shear rate for inducing aggregate formation was decreased to 50% by Tyr2561 compared with Phe2561. Differences in C-domain circular dichroism spectra resulting from Tyr2561 suggest an increased shear sensitivity of VWF as a result of altered association of the C domains that disrupts the normal dimer interface. In summary, our data emphasize the functional effect of the VWF C4 domain for VWF-mediated platelet aggregation in a shear-dependent manner and provide the first evidence that a functional variant of VWF plays a role in arterial thromboembolism.
- Published
- 2019
- Full Text
- View/download PDF
37. Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor
- Author
-
Xu, Emma-Ruoqi, von Bülow, Sören, Chen, Po-Chia, Lenting, Peter J., Kolšek, Katra, Aponte-Santamaría, Camilo, Simon, Bernd, Foot, Jaelle, Obser, Tobias, Schneppenheim, Reinhard, Gräter, Frauke, Denis, Cécile V., Wilmanns, Matthias, and Hennig, Janosch
- Abstract
Von Willebrand factor (VWF) is a key player in the regulation of hemostasis by promoting recruitment of platelets to sites of vascular injury. An array of 6 C domains forms the dimeric C-terminal VWF stem. Upon shear force activation, the stem adopts an open conformation allowing the adhesion of VWF to platelets and the vessel wall. To understand the underlying molecular mechanism and associated functional perturbations in disease-related variants, knowledge of high-resolution structures and dynamics of C domains is of paramount interest. Here, we present the solution structure of the VWF C4 domain, which binds to the platelet integrin and is therefore crucial for the VWF function. In the structure, we observed 5 intra- and inter-subdomain disulfide bridges, of which 1 is unique in the C4 domain. The structure further revealed an unusually hinged 2-subdomain arrangement. The hinge is confined to a very short segment around V2547 connecting the 2 subdomains. Together with 2 nearby inter-subdomain disulfide bridges, this hinge induces slow conformational changes and positional alternations of both subdomains with respect to each other. Furthermore, the structure demonstrates that a clinical gain-of-function VWF variant (Y2561) is more likely to have an effect on the arrangement of the C4 domain with neighboring domains rather than impairing platelet integrin binding.
- Published
- 2019
- Full Text
- View/download PDF
38. A mutation of the human EPHB2 gene leads to a major platelet functional defect
- Author
-
Berrou, Eliane, Soukaseum, Christelle, Favier, Rémi, Adam, Frédéric, Elaib, Ziane, Kauskot, Alexandre, Bordet, Jean-Claude, Ballerini, Paola, Loyau, Stephane, Feng, Miao, Dias, Karine, Muheidli, Abbas, Girault, Stephane, Nurden, Alan T., Turro, Ernest, Ouwehand, Willem H., Denis, Cécile V., Jandrot-Perrus, Martine, Rosa, Jean-Philippe, Nurden, Paquita, and Bryckaert, Marijke
- Abstract
The ephrin transmembrane receptor family of tyrosine kinases is involved in platelet function. We report the first EPHB2 variant affecting platelets in 2 siblings (P1 and P2) from a consanguineous family with recurrent bleeding and normal platelet counts. Whole-exome sequencing identified a c.2233C>T variant (missense p.R745C) of the EPHB2 gene. P1 and P2 were homozygous for this variant, while their asymptomatic parents were heterozygous. The p.R745C variant within the tyrosine kinase domain was associated with defects in platelet aggregation, αIIbβ3 activation, and granule secretion induced by G-protein–coupled receptor (GPCR) agonists and convulxin, as well as in thrombus formation on collagen under flow. In contrast, clot retraction, flow-dependent platelet adhesion, and spreading on fibrinogen were only mildly affected, indicating limited effects on αIIbβ3 outside-in signaling. Most importantly, Lyn, Syk, and FcRγ phosphorylation, the initial steps in glycoprotein VI (GPVI) platelet signaling were drastically impaired in the absence of platelet–platelet contact, indicating a positive role for EPHB2 in GPVI activation. Likewise platelet activation by PAR4-AP showed defective Src activation, as opposed to normal protein kinase C activity and Ca2+ mobilization. Overexpression of wild-type and R745C EPHB2 variant in RBL-2H3 (rat basophilic leukemia) cells stably expressing human GPVI confirmed that EPHB2 R745C mutation impaired EPHB2 autophosphorylation but had no effect on ephrin ligand-induced EPHB2 clustering, suggesting it did not interfere with EPHB2-ephrin–mediated cell-to-cell contact. In conclusion, this novel inherited platelet disorder affecting EPHB2 demonstrates this tyrosine kinase receptor plays an important role in platelet function through crosstalk with GPVI and GPCR signaling.
- Published
- 2018
- Full Text
- View/download PDF
39. A mutation of the human EPHB2gene leads to a major platelet functional defect
- Author
-
Berrou, Eliane, Soukaseum, Christelle, Favier, Rémi, Adam, Frédéric, Elaib, Ziane, Kauskot, Alexandre, Bordet, Jean-Claude, Ballerini, Paola, Loyau, Stephane, Feng, Miao, Dias, Karine, Muheidli, Abbas, Girault, Stephane, Nurden, Alan T., Turro, Ernest, Ouwehand, Willem H., Denis, Cécile V., Jandrot-Perrus, Martine, Rosa, Jean-Philippe, Nurden, Paquita, and Bryckaert, Marijke
- Abstract
The ephrin transmembrane receptor family of tyrosine kinases is involved in platelet function. We report the first EPHB2variant affecting platelets in 2 siblings (P1 and P2) from a consanguineous family with recurrent bleeding and normal platelet counts. Whole-exome sequencing identified a c.2233C>T variant (missense p.R745C) of the EPHB2gene. P1 and P2 were homozygous for this variant, while their asymptomatic parents were heterozygous. The p.R745C variant within the tyrosine kinase domain was associated with defects in platelet aggregation, αIIbβ3 activation, and granule secretion induced by G-protein–coupled receptor (GPCR) agonists and convulxin, as well as in thrombus formation on collagen under flow. In contrast, clot retraction, flow-dependent platelet adhesion, and spreading on fibrinogen were only mildly affected, indicating limited effects on αIIbβ3 outside-in signaling. Most importantly, Lyn, Syk, and FcRγ phosphorylation, the initial steps in glycoprotein VI (GPVI) platelet signaling were drastically impaired in the absence of platelet–platelet contact, indicating a positive role for EPHB2 in GPVI activation. Likewise platelet activation by PAR4-AP showed defective Src activation, as opposed to normal protein kinase C activity and Ca2+mobilization. Overexpression of wild-type and R745C EPHB2 variant in RBL-2H3 (rat basophilic leukemia) cells stably expressing human GPVI confirmed that EPHB2 R745C mutation impaired EPHB2 autophosphorylation but had no effect on ephrin ligand-induced EPHB2 clustering, suggesting it did not interfere with EPHB2-ephrin–mediated cell-to-cell contact. In conclusion, this novel inherited platelet disorder affecting EPHB2 demonstrates this tyrosine kinase receptor plays an important role in platelet function through crosstalk with GPVI and GPCR signaling.
- Published
- 2018
- Full Text
- View/download PDF
40. A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation
- Author
-
Muczynski, Vincent, Casari, Caterina, Moreau, François, Aymé, Gabriel, Kawecki, Charlotte, Legendre, Paulette, Proulle, Valerie, Christophe, Olivier D., Denis, Cécile V., and Lenting, Peter J.
- Abstract
Von Willebrand factor (VWF) modulates factor VIII (FVIII) clearance and the anti-FVIII immune response. Despite the high affinity that defines the FVIII/VWF interaction, association/dissociation kinetics dictates 2% to 5% FVIII being present as free protein. To avoid free FVIII when studying the FVIII-VWF complex in vivo, we designed a FVIII-nanobody fusion protein, with the nanobody part being directed against VWF. This fusion protein, designated FVIII-KB013bv, had a 25-fold higher affinity compared with B-domainless FVIII (BDD-FVIII) for VWF. In vitro analysis revealed full cofactor activity in 1-stage clotting and chromogenic assays (activity/antigen ratio 1.0 ± 0.3 and 1.1 ± 0.3, respectively). In vivo, FVIII-013bv displayed a twofold increased mean residence time compared with BDD-FVIII (3.0 hours vs 1.6 hours). In a tail clip–bleeding assay performed 24 hours after FVIII infusion, blood loss was significantly reduced in mice receiving FVIII-KB013bv vs BDD-FVIII (15 ± 7 μL vs 194 ± 146 μL; P = .0043). Unexpectedly, when examining anti-FVIII antibody formation in FVIII-deficient mice, the immune-response toward FVIII-KB013bv was significantly reduced compared with BDD-FVIII (1/8 vs 14/16 mice produced anti-FVIII antibodies after treatment with FVIII-KB013bv and BDD-FVIII, respectively). Our data show that a stabilized interaction between FVIII and VWF is associated with a prolonged survival of FVIII and a reduced immune response against FVIII.
- Published
- 2018
- Full Text
- View/download PDF
41. A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation
- Author
-
Muczynski, Vincent, Casari, Caterina, Moreau, François, Aymé, Gabriel, Kawecki, Charlotte, Legendre, Paulette, Proulle, Valerie, Christophe, Olivier D., Denis, Cécile V., and Lenting, Peter J.
- Abstract
Von Willebrand factor (VWF) modulates factor VIII (FVIII) clearance and the anti-FVIII immune response. Despite the high affinity that defines the FVIII/VWF interaction, association/dissociation kinetics dictates 2% to 5% FVIII being present as free protein. To avoid free FVIII when studying the FVIII-VWF complex in vivo, we designed a FVIII-nanobody fusion protein, with the nanobody part being directed against VWF. This fusion protein, designated FVIII-KB013bv, had a 25-fold higher affinity compared with B-domainless FVIII (BDD-FVIII) for VWF. In vitro analysis revealed full cofactor activity in 1-stage clotting and chromogenic assays (activity/antigen ratio 1.0 ± 0.3 and 1.1 ± 0.3, respectively). In vivo, FVIII-013bv displayed a twofold increased mean residence time compared with BDD-FVIII (3.0 hours vs 1.6 hours). In a tail clip–bleeding assay performed 24 hours after FVIII infusion, blood loss was significantly reduced in mice receiving FVIII-KB013bv vs BDD-FVIII (15 ± 7 μL vs 194 ± 146 μL; P= .0043). Unexpectedly, when examining anti-FVIII antibody formation in FVIII-deficient mice, the immune-response toward FVIII-KB013bv was significantly reduced compared with BDD-FVIII (1/8 vs 14/16 mice produced anti-FVIII antibodies after treatment with FVIII-KB013bv and BDD-FVIII, respectively). Our data show that a stabilized interaction between FVIII and VWF is associated with a prolonged survival of FVIII and a reduced immune response against FVIII.
- Published
- 2018
- Full Text
- View/download PDF
42. Impact of PI3Kα (Phosphoinositide 3-Kinase Alpha) Inhibition on Hemostasis and Thrombosis
- Author
-
Laurent, Pierre-Alexandre, Hechler, Béatrice, Solinhac, Romain, Ragab, Ashraf, Cabou, Cendrine, Anquetil, Typhaine, Severin, Sonia, Denis, Cécile V., Mangin, Pierre H., Vanhaesebroeck, Bart, Payrastre, Bernard, and Gratacap, Marie-Pierre
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2018
- Full Text
- View/download PDF
43. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets
- Author
-
Casari, Caterina, Paul, David S., Susen, Sophie, Lavenu-Bombled, Cécile, Harroche, Annie, Piatt, Raymond, Poe, Kathryn O., Lee, Robert H., Bryckaert, Marijke, Christophe, Olivier D., Lenting, Peter J., Denis, Cécile V., and Bergmeier, Wolfgang
- Abstract
von Willebrand disease (VWD) type 2B is characterized by gain-of-function mutations in von Willebrand factor (VWF), enhancing its binding affinity for the platelet receptor glycoprotein (GP)Iba. VWD type 2B patients display a bleeding tendency associated with loss of high-molecular-weight VWF multimers and variable thrombocytopenia. We recently demonstrated that a marked defect in agonist-induced activation of the small GTPase, Rap1, and integrin aIIbß3 in VWD (p.V1316M) type 2B platelets also contributes to the bleeding tendency. Here, we investigated the molecular mechanisms underlying impaired platelet Rap1 signaling in this disease. Two distinct pathways contribute to Rap1 activation in platelets: rapid activation mediated by the calcium-sensing guanine nucleotide exchange factor CalDAG–GEF-I (CDGI) and sustained activation that is dependent on signaling by protein kinase C (PKC) and the adenosine 5'-diphosphate receptor P2Y12. To investigate which Rap1 signaling pathway is affected, we expressed VWF/p.V1316M by hydrodynamic gene transfer in wild-type and Caldaggef1-/- mice. Using aIIbß3 integrin activation as a read-out, we demonstrate that platelet dysfunction in VWD (p.V1316M) type 2B affects PKC-mediated, but not CDGI-mediated, activation of Rap1. Consistently, we observed decreased PKC substrate phosphorylation and impaired granule release in stimulated VWD type 2B platelets. Interestingly, the defect in PKC signaling was caused by a significant increase in baseline PKC substrate phosphorylation in circulating VWD (p.V1316M) type 2B platelets, suggesting that the VWF–GPIba interaction leads to preactivation and exhaustion of the PKC pathway. Consistent with PKC preactivation, VWD (p.V1316M) type 2B mice also exhibited marked shedding of platelet GPIba. In summary, our studies identify altered PKC signaling as the underlying cause of platelet hypofunction in p.V1316M-associated VWD type 2B.
- Published
- 2018
- Full Text
- View/download PDF
44. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
- Author
-
Lenting, Peter J., Denis, Cécile V., and Christophe, Olivier D.
- Abstract
During the last decade, the development of improved and novel approaches for the treatment of hemophilia A has expanded tremendously. These approaches include factor VIII (FVIII) with extended half-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue factor pathway inhibitor, small interfering RNA to reduce antithrombin expression and the bispecific antibody ACE910/emicizumab. Emicizumab is a bispecific antibody recognizing both the enzyme factor IXa and the substrate factor X. By simultaneously binding enzyme and substrate, emicizumab mimics some part of the function exerted by the original cofactor, FVIII, in that it promotes colocalization of the enzyme–substrate complex. However, FVIII and the bispecific antibody are fundamentally different proteins and subject to different modes of regulation. Here, we will provide an overview of the similarities and dissimilarities between FVIII and emicizumab from a biochemical and mechanistical perspective. Such insight might be useful in the clinical decision making for those who apply emicizumab in their practice now or in the future, particularly in view of the thrombotic complications that have been reported when emicizumab is used in combination with FVIII-bypassing agents.
- Published
- 2017
- Full Text
- View/download PDF
45. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
- Author
-
Lenting, Peter J., Denis, Cécile V., and Christophe, Olivier D.
- Abstract
During the last decade, the development of improved and novel approaches for the treatment of hemophilia A has expanded tremendously. These approaches include factor VIII (FVIII) with extended half-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue factor pathway inhibitor, small interfering RNA to reduce antithrombin expression and the bispecific antibody ACE910/emicizumab. Emicizumab is a bispecific antibody recognizing both the enzyme factor IXa and the substrate factor X. By simultaneously binding enzyme and substrate, emicizumab mimics some part of the function exerted by the original cofactor, FVIII, in that it promotes colocalization of the enzyme–substrate complex. However, FVIII and the bispecific antibody are fundamentally different proteins and subject to different modes of regulation. Here, we will provide an overview of the similarities and dissimilarities between FVIII and emicizumab from a biochemical and mechanistical perspective. Such insight might be useful in the clinical decision making for those who apply emicizumab in their practice now or in the future, particularly in view of the thrombotic complications that have been reported when emicizumab is used in combination with FVIII-bypassing agents.
- Published
- 2017
- Full Text
- View/download PDF
46. A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation—Brief Report
- Author
-
Aymé, Gabriel, Adam, Frédéric, Legendre, Paulette, Bazaa, Amine, Proulle, Valérie, Denis, Cécile V., Christophe, Olivier D., and Lenting, Peter J.
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2017
- Full Text
- View/download PDF
47. Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi
- Author
-
Martinez de Lizarrondo, Sara, Gakuba, Clément, Herbig, Bradley A., Repessé, Yohann, Ali, Carine, Denis, Cécile V., Lenting, Peter J., Touzé, Emmanuel, Diamond, Scott L., Vivien, Denis, and Gauberti, Maxime
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2017
- Full Text
- View/download PDF
48. Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions
- Author
-
Muczynski, Vincent, Aymé, Gabriel, Regnault, Véronique, Vasse, Marc, Borgel, Delphine, Legendre, Paulette, Bazaa, Amine, Harel, Amélie, Loubière, Cécile, Lenting, Peter J., Denis, Cécile V., and Christophe, Olivier D.
- Abstract
Recently, we have identified scavenger receptor class A member I (SR-AI) as a receptor for coagulation factor X (FX), mediating the formation of an FX reservoir at the macrophage surface. Here, we demonstrate that the FX/SR-AI-complex comprises a third protein, pentraxin-2 (PTX2). The presence of PTX2 is essential to prevent internalization of FX by SR-AI, and the presence of FX is needed to interfere with internalization of PTX2. Binding studies showed that FX, SR-AI, and PTX2 independently bind to each other (KD,app: 0.2-0.7 μM). Surprisingly, immunoprecipitation experiments revealed that FX and PTX2 circulate as a complex in plasma, and complex formation involves the FX activation peptide. No binding of PTX2 to other vitamin K–dependent proteins was observed. Short hairpin RNA–mediated inhibition of PTX2 levels in mice resulted not only in reduced levels of PTX2, but also in similarly reduced FX levels. Moreover, PTX2 and FX levels were correspondingly reduced in SR-AI–deficient mice. Analysis of 71 human plasma samples uncovered a strong correlation between FX and PTX2 plasma levels. Furthermore, plasma samples of patients with reduced FX levels (congenital/acquired FX deficiency or after anti–vitamin K treatment) were characterized by concomitantly decreased PTX2 levels. In conclusion, we identified PTX2 as a novel partner for FX, and both proteins cooperate to prevent their SR-AI–mediated uptake by macrophages. Interestingly, their respective plasma levels are interdependent. These findings seem of relevance in perspective of ongoing clinical trials, in which plasma depletion of PTX2 is used as a therapeutical approach in the management of systemic amyloidosis.
- Published
- 2017
- Full Text
- View/download PDF
49. Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions
- Author
-
Muczynski, Vincent, Aymé, Gabriel, Regnault, Véronique, Vasse, Marc, Borgel, Delphine, Legendre, Paulette, Bazaa, Amine, Harel, Amélie, Loubière, Cécile, Lenting, Peter J., Denis, Cécile V., and Christophe, Olivier D.
- Abstract
Recently, we have identified scavenger receptor class A member I (SR-AI) as a receptor for coagulation factor X (FX), mediating the formation of an FX reservoir at the macrophage surface. Here, we demonstrate that the FX/SR-AI-complex comprises a third protein, pentraxin-2 (PTX2). The presence of PTX2 is essential to prevent internalization of FX by SR-AI, and the presence of FX is needed to interfere with internalization of PTX2. Binding studies showed that FX, SR-AI, and PTX2 independently bind to each other (KD,app: 0.2-0.7 μM). Surprisingly, immunoprecipitation experiments revealed that FX and PTX2 circulate as a complex in plasma, and complex formation involves the FX activation peptide. No binding of PTX2 to other vitamin K–dependent proteins was observed. Short hairpin RNA–mediated inhibition of PTX2 levels in mice resulted not only in reduced levels of PTX2, but also in similarly reduced FX levels. Moreover, PTX2 and FX levels were correspondingly reduced in SR-AI–deficient mice. Analysis of 71 human plasma samples uncovered a strong correlation between FX and PTX2 plasma levels. Furthermore, plasma samples of patients with reduced FX levels (congenital/acquired FX deficiency or after anti–vitamin K treatment) were characterized by concomitantly decreased PTX2 levels. In conclusion, we identified PTX2 as a novel partner for FX, and both proteins cooperate to prevent their SR-AI–mediated uptake by macrophages. Interestingly, their respective plasma levels are interdependent. These findings seem of relevance in perspective of ongoing clinical trials, in which plasma depletion of PTX2 is used as a therapeutical approach in the management of systemic amyloidosis.
- Published
- 2017
- Full Text
- View/download PDF
50. Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab
- Author
-
Bou-Jaoudeh, Melissa, Mimoun, Angelina, Delignat, Sandrine, Peyron, Ivan, Capdevila, Ladislas, Daventure, Victoria, Deligne, Claire, Dimitrov, Jordan D., Christophe, Olivier D., Denis, Cécile V., Lenting, Peter J., Proulle, Valérie, and Lacroix-Desmazes, Sébastien
- Abstract
Emicizumab is a bispecific, chimeric, humanized immunoglobulin G (IgG)4 that mimics the procoagulant activity of factor (F) VIII (FVIII). Its long half-life and subcutaneous route of administration have been life-changing in treating patients with hemophilia A (HA) with or without FVIII inhibitors. However, emicizumab only partially mimics FVIII activity; it prevents but does not treat acute bleeds. Emergency management is particularly complicated in patients with FVIII inhibitors receiving emicizumab prophylaxis in whom exogenous FVIII is inefficient. We have shown recently that Imlifidase (IdeS), a bacterial IgG-degrading enzyme, efficiently eliminates human anti-FVIII IgG in a mouse model of severe HA with inhibitors and opens a therapeutic window for the administration of exogenous FVIII.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.